$236B in Revenue Expires by 2030. The Bottleneck Isn't Science.
Patents for 190 drugs — including 69 blockbusters — expire by 2030, putting $236 billion at risk (Deloitte). Every major pharma company is responding the same way: scale the portfolio. More programs, more modalities, more sites — same headcount. The question is whether operational infrastructure can keep up.
The Patent Cliff — By the Numbers
Six Companies. One Pattern. Who Industrializes First?
Portfolio-scale operations are underway. Blockbuster revenues decline while pipeline volumes surge. The organizations that industrialize fastest will define the next era of pharmaceutical R&D.
Expanding beyond Keytruda with a diversified oncology, cardiovascular, and immunology portfolio. Pipeline must replace $25B+ in peak Keytruda revenue before patent expiration.
Post-COVID restructuring centered on volume: 110+ candidates across oncology, immunology, and rare disease. Targeting $20B in new revenue from pipeline launches by 2030.
Aggressive growth target: $80B revenue by 2030 with over 180 projects in the pipeline. Oncology, rare disease, and biopharmaceuticals driving the portfolio expansion.
Replacing biosimilar losses from Avastin, Herceptin, and Rituxan with a next-generation pipeline spanning personalized medicine, ophthalmology, and neuroscience.
Mounjaro and Zepbound propelling growth, but the pipeline extends to Alzheimer's, oncology, and immunology. Manufacturing and CMC capacity are the binding constraints.
GLP-1 dominance funding aggressive portfolio expansion into cardiovascular, NASH, and rare blood disorders. Building 5 new manufacturing sites simultaneously to meet demand.
The portfolio pipeline is the only replacement for what's about to expire. Yet the operating model hasn't changed. Each new program still requires the same manual work to onboard instruments, reconcile data, and assemble evidence. The gap between pipeline ambition and operational capacity is the real crisis.
The Market Is Shifting from Point Solutions to Orchestration Platforms
The industry spent the last decade buying instruments and automation hardware. The next 24 months will be about making heterogeneous systems actually work together. That's an orchestration problem, not a hardware problem.
The Data Problem Behind the Pipeline Problem
Pipeline complexity is accelerating faster than the infrastructure to support it. Merck has 30+ programs in Phase 3, scaled without proportional headcount growth. Pfizer is running 32 Phase 3 programs with ~20 pivotal starts planned for 2026. AstraZeneca has 196 pipeline projects with 19 new molecular entities in late-stage. Every additional program multiplies the data integration, traceability, and reporting burden — and most organizations are absorbing that burden manually.
Deloitte projects 190 drugs losing patent protection by 2030, putting $236 billion in revenue at risk — forcing every major pharma to replace lost revenue with complex, data-intensive modalities. The FDA reports that 40% of drug shortages are demand-driven, compounding the pressure on quality systems already stretched thin. This convergence of portfolio complexity, regulatory scrutiny, and operational scale is precisely what the ZONTAL infrastructure sequence is designed to address.
The Infrastructure Gap Is Real
McKinsey argues the winning R&D stack is integrated across infrastructure, data, applications, and analytics with centralized API-based exchange. Yet Benchling's 2026 Biotech AI Report finds that only 6% of organizations report fully integrated data across R&D functions — and data quality challenges are the #1 reason AI pilots fail in regulated R&D.
Most QC labs still operate on fragmented, bolted-on technology landscapes — legacy LIMS, disconnected QMS, paper-based batch records, and manual data transcription between systems. Veeva's 2025 white paper documents the pattern: after lengthy implementations, organizations find their QC systems remain siloed from core processes, with adoption stalling at single-digit feature usage while manual workflows persist.
Industry consortia SiLA 2 and Allotrope Foundation are now standardizing instrument communication and scientific data formats across major pharma.
The convergence is clear: the lab of the future requires a unified, governed data platform — the platform ZONTAL already has.
The Data Foundation Must Come First
ELN adoption rose to 81% and cloud data platforms to 80%, while digital twins cooled to 17% (Pistoia Alliance). Markets are spending on data foundations and orchestration capabilities now, and deferring full autonomy. This validates the sequence: start at integration, compound toward AI-enabled decisions. The ICAD Principles explain why →
Every pharma company has the ambition. What's missing is the scientific intelligence infrastructure.
Every New Program Costs the Same Manual Effort
Labs generate more data than ever. The challenge is what happens next — preserving context, lineage, and governance as that data moves across instruments, systems, teams, and sites. When context breaks, scientists reconstruct sample history, reconcile results, and rebuild provenance by hand.
Unless your infrastructure compounds. When every integration makes the next one faster, when every method transfer preserves full context, when every data point carries its lineage — the marginal cost of program N+1 approaches zero.
Five Bottleneck Clusters That Block Portfolio Scale
These aren't theoretical risks — they are the operational constraints reported by enterprise lab and R&D teams across the top 20 pharma companies. Each bottleneck compounds with portfolio volume.
CMC Readiness
FDA Complete Response Letters cite manufacturing deficiencies in 65% of cases. CMC is arguably the single biggest choke point in the portfolio model — and the most data-intensive. Real-time Process Analytical Technology (PAT) and multivariate process control are required to close the gap between development knowledge and manufacturing execution.
Stability Testing at Scale
Every new product multiplies stability protocols across conditions, time points, and sites. Without portfolio-level intelligence, each study starts from scratch — no predictions, no reuse.
Tech Transfer
Site-to-site method transfer remains manual, error-prone, and undocumented. Peer-reviewed evidence confirms vendor-agnostic method transfer is the critical enabler for multi-site operations.
Cross-System Traceability
Data lives in LIMS, ELN, SDMS, MES, and instrument software — each with its own schema. Regulatory submissions require end-to-end traceability that no single system can provide.
Regulatory Submission Assembly
Assembling an IND or BLA package means reconciling evidence from dozens of systems, often manually. The operating model bottleneck is a data lineage and context preservation problem.
“CMC is arguably the single biggest bottleneck. Every process change triggers comparability studies that depend on data scattered across a dozen systems.”
AI Won't Fix What Infrastructure Hasn't Solved
77% of pharma labs expect to deploy AI within two years, but only 11% have the governed data foundation to make it work (Pistoia Alliance / Deloitte, 2024). The gap between AI ambition and AI readiness is an infrastructure problem — not a model problem.
Ungoverned Data Blocks AI
AI models trained on unvalidated, siloed instrument data produce results that regulatory teams cannot trust. Every AI capability depends on the governed integration and scientific context that infrastructure provides.
Context Makes AI Useful
Raw chromatography files are noise to an AI. Governed data with method context, sample lineage, and instrument provenance is signal. Scientific context transforms instrument output into AI-ready scientific data.
Supervised Autonomy, Not Hype
The path forward is supervised autonomy — AI-assisted workflows with configurable oversight, from human-in-the-loop approval gates to fully autonomous execution. Scientists stay in control. Infrastructure enables the trust.
The portfolio pivot is an infrastructure problem. We built the infrastructure.
The bottlenecks are known. The evidence is clear. The question is whether your systems compound with each new program — or start from scratch every time.